Skip to main content

bupropion

Generic: Bupropion·Brand: Aplenzin, Auvelity, BUPROPION HYDROCHLORIDE, Contrave, FORFIVO XL, Forfivo, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, Wellbutrin, ZYBAN

bupropion: 9 clinical trials tracked.

bupropion evidence translation

What we can confirm

9 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about bupropion, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence6 indications · 7 study sponsors
Clinical Trials (9)

Abstinence Reinforcement Therapy for Veterans Who Smoke Tobacco and Are Experiencing Homelessness

Not yet recruiting

Primary endpoint: Number of participants whose self-report of prolonged smoking abstinence is bioverified

InterventionalRandomizedopen120 targetStarted 2027-03Completion 2030-091 site · United StatesVA Office of Research and Development

A Randomized, Double-Blind, Placebo and Active-Controlled Trial to Evaluate the Efficacy and Safety of AXS-05 for Smoking Cessation in Adults

NCT07766655·Phase 3·AXSM
Recruiting

Primary endpoint: 4-Week Continuous Smoking Abstinence Rate

InterventionalRandomizeddouble705 targetStarted 2026-08Completion 2027-129 sites · United StatesAxsome Therapeutics, Inc.

A Phase 1, First-in-human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VX-433 and Its Effects on the Pharmacokinetics of Midazolam and Bupropion

NCT07584434·Phase 1·VRTX
Recruiting

Primary endpoint: Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

InterventionalRandomizedquadruple118 targetStarted 2026-05Completion 2027-031 site · United StatesVertex Pharmaceuticals Incorporated

Phase 1, 2-Cohort, Open-label, Fixed-sequence, Drug-drug Interaction Study to Evaluate the Effect of Repotrectinib on the Pharmacokinetics of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

NCT07223671·Phase 1·BMY
Completed

Primary endpoint: Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of AUC (0-T) of Probe Substrate With Repotrectinib

Interventionalopen30 enrolledStarted 2025-12Completion 2026-031 site · United StatesBristol-Myers Squibb

Effectiveness of Semaglutide 2.4 mg vs. Commercially Available Medications for Chronic Weight Management in Participants With Obesity in a Multi-employer Setting in The US - a Pragmatic Clinical Study

NCT05579249·Phase 4·NVO
Completed

Primary endpoint: Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no)

InterventionalRandomizedopen500 enrolledStarted 2023-01Completion 2024-111 site · United StatesNovo Nordisk A/S

A Randomized Controlled Trial to Determine the Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette

NCT05205811·Phase 3·GHRS
Completed

Primary endpoint: Complete Switching From Combustible Cigarettes to JUUL e-cigarette as measured by Exhaled carbon monoxide (CO)

InterventionalRandomizeddouble180 enrolledStarted 2021-12Completion 2025-102 sites · United StatesRose Research Center, LLC

CPT-SMART for Treatment of PTSD and Cigarette Smoking

NCT03978442·Phase 4·GHRS
Completed

Primary endpoint: Number of Participants Whose Self-report of 7 Day Point Prevalence Abstinence From Smoking is Bioverified

InterventionalRandomizedopen115 enrolledStarted 2019-11Completion 2025-101 site · United StatesVA Office of Research and Development

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting

Primary endpoint: M/P ratio

Observational1,600 targetStarted 2018-10Completion 2027-0722 sites · Canada, United StatesDuke University

Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer

NCT03180294·Phase 2·CGON
Completed

Primary endpoint: Change From Baseline at 9 Weeks in the Desire Subscore of the Female Sexual Function Index ("Sexual Desire")

InterventionalRandomizeddouble230 enrolledStarted 2017-05Completion 2021-0250 sites · United StatesNRG Oncology